ZGNX

ZX008

Lennox-Gastaut syndrome

Stage (next event)

Expected Date

Phase 3 (Full Data Presentation at AES)

December 7, 2020

Catalyst Info & Data Links

TITLE: ZX008 in Lennox-Gastaut syndrome - sNDA Submission (Meeting with FDA)

  • ClinicalTrial.gov (NCT03355209): A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome


  • ClinicalTrial.gov (NCT03936777): A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS


PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Fenfluramine's antiepileptic activity is thought to arise from agonist activity of neuronally released serotonin (5‐HT) or via a direct agonist effect on 5‐HT receptors (5HT1D and 5HT2C). Additionally, fenfluramine has been shown to have effects on sigma 1 receptors, which have been implicated as having a role in epilepsy (Lagae et al., 2018). 

COMPETITORS

MARKET

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

Amp Core Q2 '19 Report

ZGNX imminently releasing more Ph3 data in a severe form of childhood epilepsy

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon